Clinical Trials Browser

Terminated × Neoplasms × ibrutinib × Clear all

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell